How the LYMErix Lyme Disease Vaccine was Pulled from the Market Patricia Smith, president of LDA, identifies lessons we can learn from the LYMErix Lyme disease vaccine story and pitfalls we can hopefully avoid in the future.

By Pat Smith

You must be a member to access this content.

If you are already a member, log in below. Otherwise, become a member today to access the full content of this article and the full library of Lyme Times articles.
* Physician Directory Memberships do not have access to the Lyme Times.

Page 2 of 2